Saturday, April 17, 2021

E-message to Political Leaders

 

2021 April 16

Doug Ford, Premier of Ontario, Christine Elliott, Minister of Health (Ontario), Justin Trudeau, Prime Minister of Canada, Patty Hajdu, Minister of Health (Canada), Jagdeep Singh, NDP Leader, Erin O’Toole, PC leaders, Mark Gerretson, MP for Kingston and the Islands   c.c. Dean Allison, MP for Niagara West

Dear Honourable Leaders:

It’s time to look outside of the box, by that I mean the vaccine box. As good as they are, vaccines and hygiene practices alone are not solving the pandemic problem as it is described every day by the news media. It’s time to look at pharmaceutical help in general, and at ivermectin in particular. I am attaching a copy of one of the best meta-analyses on ivermectin for COVID-19; it is the British Ivermectin Review Panel report led by Dr. Tess Lawrie a veteran of over 50 Cochrane Systematic Reviews. The key information is that ivermectin as hospital treatment is 68% effective in reducing deaths and 86% effective as a prophylactic. Moreover, a number of physicians outside of Canada have reported excellent success with this drug; for example an Idaho doctor, Ryan Cole, reported that all 42 of the patients that he treated with ivermectin rebounded within two days.

What is the potential benefit? Ivermectin could relieve the hospitals immediately. It could save lives. It could save the health of health care workers. It could save $billions. It would cost $thousands.

What is the risk of toxicity? Ivermectin has been used against parasites in developing countries for 2-4 billion people over 40 years. Since 1992, 16 deaths and 4673 adverse events were reported to VigiAccess for ivermectin compared with remdesivir’s 417 deaths and 5489 adverse events since 2020. Ivermectin is probably safer than Aspirin.

Why have ivermectin benefits been muffled? I suggest that WHO cannot afford to irritate Merck, the donor of all the ivermectin needed for the WHO parasite program. While ivermectin is off-patent, Merck has potentially profitable anti-virals such as molnupiravir in development. As ivermectin effectiveness as a prophylactic is similar to that of vaccines, it is a financial risk to COVID-19 vaccine vendors.

How is ivermectin approval impaired? Opponents simply insist that gold standard large-scale, randomized, double-blind, placebo-controlled trials are required. Such trials are beyond the resources of virtually all teams in developing countries where the research has been instigated by independent doctors and scientists.

Why have federal and provincial advisory bodies not approved ivermectin? To a large extent, these panels have taken advice from WHO because of its global imprimatur. Moreover they do not have the experience or expertise of Dr. Lawrie’s Evidence Based Consultancy.

What have I done? A few colleagues and I have petitioned the Government of Canada, and the petition (e-3265) has over 2000 signatures in the three weeks since it was mounted on March 25. It will be presented to the House by MP Dean Allison. I have had signees tell me that they have obtained ivermectin through unconventional sources, such as meant for animals. As Canadians use unconventional ivermectin, we contribute to potential toxicities by depriving them of approved human product. This alone should prompt us to make it readily available to people; remember it is as safe as over-the-counter drugs such as Aspirin and Tylenol.

In closing, I ask that you immediately consider approving ivermectin use in our hospitals and community. To do anything less is wasteful and unethical; I don’t want our province and country to have blood on its hands.

Your sincerely,

Kanji Nakatsu

(While we dither, people die; ivermectin might have saved 40 of the 53 Canadians who died yesterday)


No comments:

Post a Comment